Proteon Therapeutics Inc (PRTO) 銘柄情報

Thanks for doing a technical analysis video on a stock the day before it was converted into shares of another company on a 40 to 1 basis without providing even one dose of discussion about the terms of the corporate action. You are literally the blind leading the blind.

I guess the dollar volume today was greater than yesterday’s but the range was huge and the spread was $3+ wide at all times. Maybe this stock gets a bit more liquid in the next few days, the old Artara stock was only trading around 4K shares a day.

$33.40 is the equivalent price of yesterday’s (the last days) PRTO

This stock is NOT liquid right now

18k shares volume, high of 41.98 low of 24.65

Here is a PR on the merger

https://www.globenewswire.com/news-release/2020/01/09/1968639/0/en/ArTara-Therapeutics-Completes-Merger-Transaction-with-Proteon-Therapeutics.html

ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics
Shares of ArTara to commence trading on Nasdaq under new ticker symbol “TARA” effective January 10, 2020

Company completes previously announced equity financing of $42.5 million concurrently with the closing of the merger

Combined company will focus on developing treatments for Lymphatic Malformations and intestinal failure associated liver disease

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA) (“ArTara” or the “Company”), a clinical-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced the completion of the merger with Proteon Therapeutics, Inc. (“Proteon”) (Nasdaq: PRTO) and associated equity financing. The merged company will operate under the name ArTara Therapeutics, Inc., and its shares will commence trading on the Nasdaq Capital Market at the open of market trading on January 10, 2020, under the ticker symbol “TARA.”

“We believe that the closing of the merger signifies a transformative event that will provide ArTara with the opportunity to achieve its next level of corporate growth as we advance our pipeline of de-risked, unique solutions for rare and specialty diseases,” said Jesse Shefferman, chief executive officer of ArTara. “We look forward to achieving a number of exciting milestones in our development programs in the coming year.”

The combined company also closed an equity financing of approximately $42.5 million with a syndicate of healthcare dedicated investors. The net proceeds from this financing will fund development of ArTara’s lead assets, TARA-002 and intravenous (IV) choline chloride.

ArTara is focused on acquiring and modernizing high-potential, de-risked product candidates for rare and specialty diseases. The Company’s lead program, TARA-002, is a follow-on biologic of the innovator therapy OK-432, an inactivated Group A streptococcus bacterial preparation approved in Japan for the treatment of lymphangiomas, also known as Lymphatic Malformations or LM’s, along with several other specialty indications. ArTara plans to initially pursue development of TARA-002 for the treatment of LM’s which are rare, typically congenital, malformations of the lymphatic vasculature. TARA-002’s innovator therapy, OK-432, has been interrogated in dozens of additional indications through investigator-sponsored studies around the world and ArTara will conduct preliminary investigations into a number of these indications after advancing the LM’s program.

ArTara’s second asset, IV choline chloride, is a phospholipid substrate replacement therapy that has shown promising results in a Phase 2 study in intestinal failure associated liver disease (IFALD). ArTara’s IV choline chloride has also been granted orphan drug designation by the U.S. FDA.

The combined company will be led by Jesse Shefferman, its chief executive officer, and will be headquartered in New York.

Following the closing of the merger and the financing, the previous Proteon stockholders will own approximately 10% of the combined company, while the previous ArTara security holders and new investors will own approximately 90% of the combined company (on a fully diluted basis).

H.C. Wainwright & Co. acted as financial advisor to Proteon for the merger, and Morgan, Lewis & Bockius LLP acted as legal counsel to Proteon. Ladenburg Thalmann & Co. Inc. acted as financial advisor to ArTara, and Cooley LLP acted as legal counsel to ArTara.

About ArTara Therapeutics, Inc.
ArTara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. ArTara’s current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company’s lead program, TARA-002, is being developed for the treatment of lymphatic malformations. ArTara’s second program, IV choline chloride, is a phospholipid substrate replacement therapy in development for the treatment of IFALD. For more information, visit https://artaratx.com/for-investors/.

Forward-Looking Statements
This communication contains “forward-looking” statements, including, without limitation, statements related to the anticipated benefits of the transactions contemplated by the merger and the financing and the related transactions, the anticipated benefits of the sale of $42.5 million of ArTara’s common stock to certain stockholders, the anticipated trading of the combined company’s stock on the Nasdaq Capital Market, and statements related to ArTara’s development programs. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon ArTara’s current expectations. Forward-looking statements involve risks and uncertainties. ArTara’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, related to ArTara’s ability to successfully integrate the operations of Proteon and ArTara and achieve the potential benefits of the merger; the Company’s ability to advance its preclinical programs and the uncertain and time-consuming regulatory approval process. Additional risks and uncertainties relating to ArTara and its business can be found under the caption “Risk Factors – Risks Related to ArTara” in Proteon’s Registration Statement on Form S-4 initially filed with the SEC on November 7, 2019, as amended. ArTara expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in ArTara’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

CONTACTS

Media Contact
Karen O’Shea, Ph.D.
LifeSci Public Relations
koshea@lifescipublicrelations.com
929-469-3860

The new stock is super illiquid , I wouldn’t recommend trading it

Looks like we got 10% of the new merged company symbol tara I don't know-- I accumulated a lot of prto and knew the merger was coming.


I am sticking with what i have --and wait and see what happens for a while-- some of these fast track and orphan drugs do well, as there are government subsidies involved.

Seems to have converted to TARA

Anyone have more on this? Kind of tricky to figure out exactly what happened here

lol

* * $PRTO Video Chart 01-09-2020 * *

Link to Video - click here to watch the technical chart video

Lots of loading walls today

Grabbing the dip after the big pop today. Continuation will start tomorrow as these Hedge Funds walk this up.

PRTO trading $0.86--wow

PRTO trading $0.70 after hours, and got as high as $0.75...haven't seen any news but it's running

PRTO having a nice day, trading $0.635 / up 15.5%

$PRTO: Looks good now.... $1.50 by EOW


Lets make it happen.


The ArTARA era is about to begin with Proteon



GO ArTARA.... should be nice in JP Morgan conference next week.


GO $PRTO



[/img]

$PRTO: $SAVA-like move coming here


ArTARA finalizations underway.


JPMorgan conference next week.


Lets see it happen folks.


GO $PRTO

$PRTO : 10.2% of ArTara should value us at $0.85/sh


At a Minimum.


MarketValue is only at $9Million so far.


Maybe if we're lucky we get higher than that based on Wainrights assessment.





GO $PRTO

Very nice Golf
https://stockcharts.com/h-sc/ui?s=PRTO&p=D&b=5&g=0&id=p49227715517
https://investorshub.advfn.com/boards/replies.aspx?msg=152142822

Some other things that came to be true in 2019..
https://www.chicagotribune.com/suburbs/post-tribune/opinion/ct-ptb-davich-amazing-kreskin-predictions-2019-st-1228-story.html
;)

nice close

Me thinks ur reading of those tea leaves was pretty good
(or have developed "intuition" like the woman folk ;)
(or got lucky [see above, lol];)
PRTO$

SHAWEEEEET!

Looks about ready mangz...

I came in here for that special offer
PRTO$

$PRTO: Name & Ticker change should be happening.


Wonder what the delay is.


News any day now.


This is the time they were expecting it to get done.


Good value here at $0.30


GO $PRTO

Grabbing some here...

What’s the holdup here

$PRTO: Lets get this Party STARTED !!!!!!!!!!!!


HAPPY THANKSGIVING !!!!!!!

$PRTO : Bullish-Flag complete here at $0.32


Breakout watch people.


Don't miss it.



All profits reaped here will head into $FELPU


GO $PRTO

Agree. It’s gonna fly.

$PRTO : Get ready to rumble... breakout coming


This flag is just about done.


This thing is about ready to roll.



TUTE ownership locked in.


Gonna be renamed shortly to ArTARA.... don't get left behind.


Now at $0.31



http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-and-artara-therapeutics-agree-combine

$10k on the bid



GO $PRTO

$PRTO: Thats what I was thinking 7wks ago

Its all about timing.


The curve is heading higher now.

$0.24 was the bottom.


GO $PRTO

Thanks Man, I was in the market
For a target,
PRTO$

$1

0.9 in no time.

Is it possible that maybe, just maybe this stock can keep going up, up and away??

MM Mofos, lol
PRTO$

$PRTO : Trying to figure out what I missed here


Pretty sure this was going to $0.84 on TUTE investment and new TARA
ticker.


Surprised its down here at $0.27 but I'm tempted to average down now.

Found the September news to be pretty bullish here for $PRTO but
I clearly read it wrong as the PPS dropped 20% from entry.


Still see upside here though.


Will try and contain optimism in the future.


Lesson learned but I think my timing was just a lil off.
Should've waited 2wks after that news before getting in.



GO $PRTO

How is this stock still listed on NASDAQ? It's been under a buck for close to six months if not more. Waiting for a nice pop before years end.

Don’t understand this company.

This continues to drop.

$PRTO: Awesome.... smart money is loading

I can see that you are one of them.

Thats how we make the EZ-Money baby !!!!!


Now at $0.295


GO $PRTO

Agreed. Ready to bounce.

$PRTO: Accumulating more here at $0.27

This will be back over $0.50 in no time.


Super value here.


GO $PRTO

$PRTO: $45Million Tute investment .... and MarketCap only $4Million


There is a vicious short squeeze that has to transpire.

Complete garbage how this has gone from $0.48 to $0.27 on such positive
news with ArTara reverse merger.


Complete garbage move.



GO $PRTO

I guess not I thought prices would’ve bottomed out in the 30 cent range. We shall see GLTU

Is there a bottom for this ?

Hahaha .84 cents by tomorrow. I hope I get to eat my words!

$PRTO: Shouldn't be a holdup really


Maybe Filings.


But things are about to really move here.


Gonna be renamed to $TARA shortly.


$45Million TUTE money coming in.


Nasdaq listing.


So we wait and see what Shefferman is about to do next.



GO $PRTO

What’s the holdup here

$PRTO: Very sorry to hear that..........

I know the people you are talking about as well.


They were calling for $100 PPS, these retards pulling numbers out of
their asses like they know everything.


Case in Point... this Numbnut on Twitter, he was pumping
$ASGXF the most........


https://twitter.com/BMoeKnows



NOw he's pumping $BANJ really hard like as if its $DCGD


Complete Shythead.



Try and avoid these jerkoffs......... challenge them if you must.
But their schpeel is the same day in day out, yet they are shit for
brains.


I'm not calling for $100 on $ASGXF... never fell for that.
I'm in it still but I don't have a huge loss, just for swing trade.




GO $PRTO

Lost a ton on asgxf. Mofo pumpers. Not you. Did you get out?

$PRTO: $0.84 by Friday


Conservative target.


Let the market settle down a lil bit.


Setting up just perfectly here with the change of control and
new Institutional Investors coming in.


Its gonna be a BIG NAME



GO $PRTO